AMRX · Amneal Pharmaceuticals, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · AMRX

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$3.02B	$2.79B	$2.39B	$2.21B	$2.09B	$1.99B
Cost of Revenue	$1.91B	$1.77B	$1.57B	$1.42B	$1.30B	$1.33B
Gross Profit	$1.11B	$1.02B	$820.57M	$784.71M	$768.97M	$628.39M
R&D	$186.18M	$190.71M	$163.95M	$195.69M	$201.85M	$179.93M
SG&A	$526.83M	$476.44M	$429.68M	$399.70M	$365.50M	$326.73M
Total Operating Expenses	-	-	-	-	-	-
D&A	$57.30M	$62.60M	$66.20M	$68.11M	$60.70M	$60.42M
Operating Income	$394.10M	$249.33M	$204.37M	($94.93M)	$152.72M	$91.16M
Interest Expense	-	-	-	-	-	-
Income Tax	$11.28M	$18.86M	$8.45M	$6.66M	$11.20M	($104.36M)
Net Income	($116.89M)	($116.89M)	($79.27M)	($270.58M)	$13.16M	$91.06M
EPS - Basic	$0.23	($0.38)	($0.48)	($0.86)	$0.07	$0.62
EPS - Diluted	$0.22	($0.38)	($0.48)	($0.86)	$0.07	$0.61

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$282.03M	$110.55M	$91.54M	$25.98M	$247.79M	$341.38M
Accounts Receivable	-	-	-	$741.79M	$662.58M	$638.89M
Inventory	$606.30M	$612.45M	$581.38M	$530.74M	$489.39M	$490.65M
Accounts Payable	-	-	-	$165.98M	$131.08M	$153.14M
Current Assets	$1.91B	$1.59B	$1.38B	$1.41B	$1.52B	$1.55B
Total Assets	$3.68B	$3.50B	$3.47B	$3.80B	$3.94B	$4.01B
Current Liabilities	$881.63M	$1.13B	$846.60M	$752.80M	$677.24M	$676.90M
Long-term Debt	$2.57B	$2.16B	$2.39B	$2.59B	$2.68B	$2.74B
Total Liabilities	-	-	-	-	-	-
Stockholders' Equity	($70.79M)	($109.27M)	$19.78M	$298.42M	$360.34M	$303.27M
Retained Earnings	($535.00M)	($607.06M)	($490.18M)	($406.18M)	($276.20M)	($286.82M)

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$339.99M	$295.10M	$345.58M	$65.10M	$241.82M	$379.00M
Investing Cash Flow	($112.26M)	($63.00M)	($69.19M)	($174.31M)	($194.18M)	($317.55M)
Financing Cash Flow	($31.53M)	($211.79M)	($212.57M)	($106.62M)	($138.12M)	$131.81M
CapEx	$70.06M	$51.92M	$43.22M	$46.41M	$47.73M	$56.45M
Free Cash Flow	$269.93M	$243.18M	$302.36M	$18.69M	$194.09M	$322.56M

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	36.9%	36.5%	34.3%	35.5%	36.7%	31.5%
Operating margin	13.1%	8.9%	8.5%	-4.3%	7.3%	4.6%
EBITDA margin	15.0%	11.2%	11.3%	-1.2%	10.2%	7.6%
Net margin	-3.9%	-4.2%	-3.3%	-12.2%	0.6%	4.6%
Free cash flow margin	8.9%	8.7%	12.6%	0.8%	9.3%	16.2%
FCF / Net income	-2.31	-2.08	-3.81	-0.07	14.75	3.54
R&D / Revenue	6.2%	6.8%	6.8%	8.8%	9.6%	9.0%
SG&A / Revenue	17.5%	17.1%	18.0%	18.1%	17.5%	16.4%
Effective tax rate	-	-	-	-	46.0%	-
Return on assets	-3.2%	-3.3%	-2.3%	-7.1%	0.3%	2.3%
Return on equity	165.1%	107.0%	-400.7%	-90.7%	3.7%	30.0%
Return on invested capital	12.5%	9.6%	6.7%	-2.6%	2.7%	2.4%
Liquidity
Current ratio	2.17	1.41	1.63	1.88	2.24	2.29
Quick ratio	1.48	0.86	0.94	1.17	1.52	1.57
Cash ratio	0.32	0.10	0.11	0.03	0.37	0.50
Leverage
Debt / Equity	-36.23	-19.78	120.62	8.69	7.44	9.02
Debt / Assets	0.70	0.62	0.69	0.68	0.68	0.68
Debt / EBITDA	5.68	6.93	8.82	-	12.56	18.05
Interest coverage	-	-	-	-	-	-
Equity multiplier	-51.96	-32.04	175.55	12.73	10.93	13.21
Liabilities / Assets	-	-	-	-	-	-
Efficiency
Asset turnover	0.82	0.80	0.69	0.58	0.53	0.50
Inventory turnover	3.14	2.90	2.71	2.67	2.66	2.71
Days sales outstanding	-	-	-	122d	116d	117d
Days inventory outstanding	116d	126d	135d	137d	137d	135d
Days payable outstanding	-	-	-	43d	37d	42d
Cash conversion cycle	-	-	-	216d	216d	210d
Valuation
P / E	57.3x	-	-	-	68.4x	7.5x
P / B	-	-	54.0x	1.0x	2.0x	2.2x
P / S	1.4x	0.9x	0.4x	0.1x	0.3x	0.3x
EV / EBITDA	14.1x	14.4x	12.4x	-	14.8x	20.3x
Growth
Revenue growth (YoY)	8.0%	16.7%	8.2%	5.7%	5.1%	22.5%
Revenue CAGR (3y)	10.9%	10.1%	6.3%	10.8%	27.2%	-
Revenue CAGR (5y)	8.7%	11.4%	18.6%	-	-	-
Gross profit growth (YoY)	9.1%	24.4%	4.6%	2.0%	22.4%	78.0%
Operating income growth (YoY)	58.1%	22.0%	-	-	67.5%	-
Net income growth (YoY)	0.0%	-47.5%	70.7%	-	-85.5%	-
EPS growth (YoY)	-	20.8%	44.2%	-	-88.5%	-
EPS CAGR (3y)	-	-	-	-	-	-
EPS CAGR (5y)	-18.5%	-	-	-	-	-
FCF growth (YoY)	11.0%	-19.6%	1517.5%	-90.4%	-39.8%	-
FCF CAGR (5y)	-3.5%	-	-	-	-	-
Book value growth (YoY)	35.2%	-	-93.4%	-17.2%	18.8%	30.7%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$3.02B total

Affordable Medicines Segment$1.75B · 57.8%

Av KARESegment$744.73M · 24.7%

Specialty Segment$528.51M · 17.5%

Product / service

$5.28B total

Subtotal Dosage Forms$1.73B · 32.8%

Oral Solid$726.38M · 13.8%

Subtotal Therapeutic Classes$528.01M · 10.0%

Distribution Service$408.46M · 7.7%

Central Nervous System$333.42M · 6.3%

Government Label$270.11M · 5.1%

Other Dosage Forms$252.42M · 4.8%

Ephinephrine Auto Injector$232.80M · 4.4%

Transdermal$187.51M · 3.6%

Injectable$161.24M · 3.1%

Hormonal Allergy$154.93M · 2.9%

Biosimilar$100.23M · 1.9%

Oral Liquid$72.82M · 1.4%

Other Therapeutic Classes$39.66M · 0.8%

Institutional$35.38M · 0.7%

Product And Service Other$30.79M · 0.6%

International$12.13M · 0.2%

License Agreement$500.0K · 0.0%

Geographic

$1.75B total

US$1.75B · 100.0%

Stability scores

Piotroski F-score

FY 2025 · 9-point quality

6/9

Neutral

✗Net income positive
✓Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
✗Long-term debt decreased
✓Current ratio improved
✗No share dilution
✓Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Pharmaceutical Preparations

Company	Revenue (last FY)	Net margin	ROE
LLY	$65.18B	31.7%	77.8%
UTHR	$3.18B	41.9%	18.8%
PFE	$62.58B	12.4%	9.0%
ZTS	$9.47B	28.2%	80.2%
VRTX	$12.00B	32.9%	21.2%

Comparing Amneal Pharmaceuticals against the 5 most active filers in the same SIC group.